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Background and purpose: Huntington’s disease (HD) is a chronic progressive 
neurodegenerative disorder with a long presymptomatic period that opens a window 
for potential therapies aimed at neuroprotection. Neuroimaging offers the potential to 
monitor disease-related progression of the disease burden (DB) using model-based 
magnetization transfer imaging.
Materials and methods: We have conducted a cross-sectional study to stratify healthy 
age-matched controls, premanifest and symptomatic HD patients (n = 30) according to 
their macromolecular depositions in the caudate nucleus. We employed a binary spin-
bath magnetization transfer (MT) method for a quantitative description of macromolecule 
deposits and interactions with their adjacent environment.
results: A region-of-interest based fuzzy clustering analysis identified representative 
clusters for several stages of the disease course related to its progression: one cluster 
represented subjects with a high DB <268 that encompassed all symptomatic HD 
patients and one presymptomatic gene carrier. The next cluster represented the pre-
symptomatic gene carriers with a very low DB >230 and healthy controls. Three further 
clusters represented transition zones between both DB levels (230–268) consisting of 
presymptomatic carriers with DB values increasing with decreasing distance from the 
cluster that indicated low DB and healthy age-matched controls.
conclusion: The proposed binary spin-bath MT method offers the potential to monitor 
DB and progression in HD. The method may augment qualitative MT techniques since it 
depicts tissue changes related to interactions between macromolecules and protons in 
disease specific brain regions that follow the neurodegenerative process.
Keywords: magnetization transfer imaging, huntington’s disease, caudate nucleus, classification, 
pre-huntington’s disease gene carriers
Abbreviations: DB, disease burden; HD, Huntington’s disease; HTT, huntingtin gene; mMT, model-based magnetization 
transfer; MT, magnetization transfer; MTR, MT ratio; PBA, Problem Behaviors Assessment; UHDRS, unified Huntington’s 
Disease Scale.
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inTrODUcTiOn
Huntington’s disease (HD) is an autosomal dominant inherited 
disorder with abnormal movements, including chorea, dystonia, 
motor impersistence, and psychiatric and cognitive impairment 
(1, 2). The disorder is related to the elongation of a CAG triplet 
repeat in the huntingtin gene (HTT), a dynamic mutation, 
whereby the disease onset is inversely correlated with the number 
of repeats. Multiple aspects underlie cellular pathology in cells 
expressing the HTT gene with elongated triplet repeats (3–5). 
Among the numerous pathways disturbed in cells bearing HTT 
gene CAG triplet expansions are gene transcription and post-
translational protein handling, energy metabolism, intracellular 
protein trafficking and metabolism, dynamic axonal transport, 
or endocytic and vesicular trafficking changes. Complex interac-
tions of these mechanisms lead to disturbed cellular function and 
to cell death. A specific degeneration is found in the striatum; 
however, numerous other regions get involved over time (6). 
Beside the loss of huntingtin function, its accumulation in 
cytoplasma and in nuclear inclusion bodies also plays a role (6). 
While methods to measure this accumulation have been readily 
established in  vitro, there is a need to develop biomarkers for 
in vivo assessment.
Structural MRI has been recognized as a surrogate biomarker 
to assess volume changes of core structures in HD brains. 
New protocols now allow fully automated morphometry (7). 
Track-HD, a prospective study within the European HD Network 
(EHDN), included 366 premanifest individuals, patients with HD 
and controls. After a 1 year follow-up period, this study demon-
strated that the rates of brain atrophy were higher in premanifest 
HD carriers and early HD patients compared to healthy controls 
even in persons far from predicted disease onset (8). Clinical 
impairment in premanifest and early HD was associated with 
specific gray matter loss in the striatal areas, the sensory and 
motor cortices for motor-dependent tasks, the visual cortex and 
cuneus, and widespread along the white matter, dependent on the 
underlying motor and neuropsychiatric testing.
Beyond T1-weighted imaging, advanced neuroimaging tech-
niques as diffusion tensor imaging, T2*-weighted relaxation time 
mapping and MR spectroscopy (MRS) have been successfully 
applied to investigate microstructural alterations associated with 
HD severity (9). However, none of these methods allow assump-
tions about the amount of accumulated huntingtin with elongated 
polyglutamine track in the basal ganglia. Magnetization transfer 
(MT) imaging has an advantage in that it determines physical 
properties that depend on the presence of macromolecules not 
directly measurable by structural imaging techniques and MRS. 
MT transmits radio-frequency energy to protons bound to mac-
romolecules within the tissue of interest, e.g., the gray matter of the 
human brain. Dependent on the macromolecule concentration, 
energy is transferred to free soluble protons via dipole–dipole 
interactions. In relation to the degree of coupling between bound 
and unbound protons, the free water pool becomes partially satu-
rated and can be subsequently imaged using routine RF pulses and 
gradients. Model-based magnetization transfer (mMT) imaging 
is a refined MT method that goes beyond the clinically used MT 
ratio (MTR) and allows the investigation of the fundamental 
parameters that describe the basic MT interaction processes. In 
contrast to MTR, the MT process and the relaxation processes 
are well separated to avoid statistically misleading results (10). 
According to this separation of the fundamental MT and relaxa-
tion parameters, the interaction and coupling of the HD specific 
macromolecules with its environment can be fully described and 
related to the underlying pathological process.
In this study, we have investigated differences in the mMT 
parameters mentioned above in two cohorts of HD mutation 
carriers, one during clinically manifested disease and one during 
a preclinical stage without motor symptoms and cognitive decline 
in comparison to a group of healthy control persons. We hypoth-
esized that changes in mMT parameters describing the restricted 
and free proton pool and the restricted-to-free proton pool size 
ratio would allow to identify different mMT profiles between HD 
carriers and patients.
MaTerials anD MeThODs
study Participants
Three cohorts of participants have been included in this pro-
spective study, which has been approved by the ethics committee 
of the state of Bern. All participants gave informed consent or, in 
the case of a legal representative confirming, assent for clinical 
examination and for MMT studies. The cohort of affected gene 
carriers included male and female individuals, 18 or older, with 
clinically manifest HD and a known mutation including the 
exact number of CAG triplet repeats. At the time of examina-
tion, they were in a middle state of motor involvement with a 
total score higher than 30 according to the motor part of the 
unified Huntington’s Disease Scale (UHDRS) and a diagnostic 
confidence of motor manifestation of 5. The value of their 
independence scale was between 50 and 75%. Participants with 
premanifest HD were male and female HD mutation carrier, 18 
or older. Their motor score in the UHDRS was lower than 4, and 
their value 100% on the independence scale. Control persons 
included men and women age 18 or older without neurological 
or psychiatric history and family history.
Exclusion criteria in all three groups included history or 
epileptic seizures or meningoencephalitis, known other brain 
lesions other than HD, severe claustrophobia, ongoing drug 
and/or alcohol abuse, and medication with amphetamines, 
methylphenidate, foscarnet, ganciclovir, ritonavir, cocaine, 
gamma-hydroxybutyrate, theophylline, chloroquine, mefloquine, 
imipenem, penicillin, ampicillin, cephalosporins, metronidazole, 
isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, 
methotrexate, cytosine arabinoside, lithium, systemic antihis-
tamines, and systemic sympathomimetics. Participants with 
magnetic (metallic) particles in the scull or brain, with a cardiac 
pacemaker or deep brain stimulators, were excluded, as well as 
patients that could not undergo MRI exam due to severe motion.
Gene carrier and HD participants were examined using the 
motor part of the UHDRS. The cognitive battery included the 
verbal fluency test with a three-letter fluency performed in each 
3Wiest et al. mMT Imaging in HD
Frontiers in Neurology | www.frontiersin.org September 2017 | Volume 8 | Article 465
1  min and a categorical fluency test (animals) for 1  min; the 
symbol-digit modality test; the Stroop test (color naming, read-
ing, and interference); and the trail making tests A and B. The 
psychiatric evaluation was performed with the problem behavior 
assessment for HD, short form (11). The examination was done as 
part of the participation in the Registry protocol, version 3, of the 
EHDN. To compare the values of the groups, the disease burden 
score (DBS) was calculated according to the following formula: 
Age × (CAG repeat number in the larger allele − 35.5).
mMT imaging
The protons in physiological systems as well as during pathologi-
cal macromolecular accumulation can be described as existing in 
two pools: as free or bound protons. The mMT model discrimi-
nates interstitial bulk (free) water deposits associated with aging 
and atrophy (T2f) and the reservoir of restricted protons of mac-
romolecules (T2r). The restricted-to-free proton pool size ratio 
(F) quantifies the macromolecular over liquid content within an 
individual voxel and is assumed to be a proxy for the content of 
macromolecular storage in HD brains. Spin-density free proton 
(SDf) is a marker for density of free protons within the tissue. 
We made use of a binary spin-bath MT model (12) to separate 
effects related to a direct saturation of the free pool and real MT 
effects and determining the fundamental physical parameters 
that characterize the shape of the MT spectra: the relative size of 
the restricted proton pool (F), the magnetization exchange rates 
between the free and the restricted pools (kf [free → restricted], 
kr [restricted →  free]), the T2 relaxation time of the restricted 
pool (T2r), and the relaxation times T1 and T2f of the free pool, 
which were determined in separate experiments on the basis of 
the Bloch equations (13). The restricted-to-free proton pool size 
ratio (F) quantifies the macromolecular over free proton content 
within an individual voxel. The exchange rates (kf, kr) express the 
through-space transfer of magnetization between the reservoirs 
by magnetic dipole-dipole coupling and chemical exchange. The 
T2r relaxation time of the restricted pool can be interpreted as a 
marker for the type of the macromolecules and its coupling to the 
environment (13, 14). A schematic description of the method is 
provided in Figure 1.
Mr sequence
The experiments were performed on a 3.0 T whole-body scanner 
(Siemens Magnetom Verio TIM, Siemens Erlangen, Germany) 
equipped with a 12 channel head coil. The acquisition time for the 
entire protocol (3D-T1, mMT) approximated 30 min.
The experimental base for the quantification of the MT 
effects is a repeated presaturation of the sample with Gaussian 
radio-frequency pulses irradiated at different off-resonant fre-
quencies. The MTR was calculated by relating the MT images 
acquired at Δf = 1.00 kHz to the data without presaturation (M0): 
MTR =  100 ×  [M0 −  mol/L(Δf =  1.0)]/M0. The MT-weighted 
images were acquired by using a set of seven gradient-echo 
FLASH sequences with Gaussian-modulated presaturation pulses 
at frequency offsets (Δf) of 1.00, 2.00, 4.00, 8.00, 10.00, 12.00, 
and 16.00  kHz, according to the central 1H Larmor frequency 
[TR = 300 ms, TE = 4.18 ms, αEXC = 20°, αMT = 540° (Gaussian), 
section thickness  =  4  mm (gap 0), 16 sections (interleaved), 
FOV = 256 mm, 128 × 128 matrix (data interpolated to 256 × 256)].
Structural MR imaging included a T1-weighted, sagittal-
oriented 3D magnetization-prepared rapid acquisition of 
gradient-echo sequence (TR/TE/TI, 2,000/3.42/1,100 ms; matrix 
size 256 ×  256; FOV, 256 mm ×  256 mm; flip angle, 15°; slab, 
160 mm) with a 1-mm3 isovoxel resolution.
Data extraction and image calculation
We focused the analysis on the mMT measures in the caudate 
nucleus (NC) as a single region-of-interest (ROI), since this 
brain area revealed well-replicated findings of huntingtin-related 
damage in prodromal-HD subjects (6). The non-linear fitting of 
the theoretic MT model-based signal to the measured MT signal 
intensity within each imaging voxel was accomplished by using 
a Levenberg–Marquardt algorithm, which provides the optimal 
parameter values for each voxel in a least-squares sense. Following 
this approach, complete new images were calculated that repre-
sent the different parameter values for each voxel (13, 14) for 
further ROI analysis. An expert neuroradiologist with 15 years of 
experience manually traced the NC on a reference data template 
in Montreal Neurological Institute space (SPM Anatomy toolbox, 
colin27T11). The borders of the NC were identified on the T1w 
image as the gray matter adjacent to the lateral ventricle, from the 
caudate head at the rostral border of the internal capsule to its tail 
in close relationship to the amygdala following the caudate trac-
ing guidelines by Westmoreland and Cretsinger.2 To project these 
region from a reference data template in Montreal Neurological 
Institute space (SPM Anatomy toolbox, colin27T1, see text 
footnote 1) into the individual brains, the SPM5 (Wellcome 
Department of Imaging Neuroscience, London, UK) warping 
algorithms and Jacobian matrices were used.
statistics
The classification was performed with a Gustafson–Kessel 
algorithm (15). The Gustafson–Kessel algorithm associates each 
cluster with both a point and a matrix, representing the cluster 
center and its covariance. This technique is capable of detecting 
hyperellipsoidal clusters of different sizes and orientations by 
adjusting the covariance matrix of data, thus overcoming the 
drawbacks of a conventional fuzzy-c-means algorithm. This 
choice is essential because it makes the classification more robust 
against outliers and noise.
After clustering in the high-dimensional space the essential 
classification is performed in a two-dimensional representation 
which is accomplished by a principle component analysis. The 
two main components with the largest eigenvalues were used for 
the final classification.
The program for the cluster analysis is an in-house-written 
software based on the Matlab (MathWorks, Natick, MA, USA) 
environment. The postprocessing procedure is fully automated 
and has been described in detail previously (13, 14).
1 https://www.fz-juelich.de/SharedDocs/Downloads/INM/INM-1/DE/Toolbox/
Toolbox_22c.html?nn=563092.
2 https://www.icts.uiowa.edu.
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FigUre 1 | Continued
TaBle 1 | Clinical data (clinically asymptomatic gene carriers and symptomatic 
HD patients).
Demographic data and 
clinical scores
carriers, 
n = 10 (f = 9)
Manifest, n = 10 
(f = 5)
Paired t-test
Mean sD Mean sD
Age 40.6 9.1 54.2 12.7 0.04
CAG repeats 42.5 2.4 43.7 2.8 n.s.
Disease burden score 266.4 73.5 443.0 123.4 0.002
Total motor score 1.3 1.1 51.0 24.6 0.00001
Total functional score 5.7 0.3 12.9 3.4 0.0001
UHDRS, Unified Huntington’s Disease Scale; m, male; f, female; HD, Huntington’s 
disease.
FigUre 1 | Continued  
Schematic illustration of the region-based multiparametric model-based magnetization transfer (mMT) analysis: (1) mMT is sensitive to measures of macromolecular 
tissue accumulation. Changes in the restricted and free proton pool and the restricted-to-free proton pool size ratio in a region of interest analysis (caudate nucleus) 
are used to discriminate between presymptomatic and symptomatic stages of Huntington’s disease (HD). (2) The protons can be described as existing in two pools: 
as free or bound protons. The mMT model discriminates interstitial bulk (free) water deposits and the reservoir of restricted protons of macromolecules. The 
restricted-to-free proton pool size ratio quantifies the macromolecular over liquid content within an individual voxel and is hypothesized to be a proxy for the content 
of macromolecular storage in HD brains. (3) The experimental base for the quantification of the magnetization transfer effects is a repeated presaturation of the 
sample with Gaussian RF pulses irradiated at different off-resonant frequencies. Normalized mMT absorption spectra for each brain compartment (CSF, white 
matter, gray matter outlined in gray), the amount of abnormally accumulated large proteins (red) vs. physiological conditions (blue) enable groupwise stratifications of 
patients, pre-HD carriers and HC. (4) A fuzzy clustering algorithm with subsequent principal component analysis (PCA) for the projection on two dimensions is 
applied. The axes correspond to the dimensions of the projected data using the eigenvectors with the largest eigenvalues calculated by the PCA—of note, the other 
main components only contain noise and irrelevant information.
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resUlTs
Participants
Twenty persons with increased numbers of CAG repeats on the 
larger huntingtin allele (39–49) were included. None of them 
underwent intubation. Ten symptomatic persons had 41–49 CAG 
repeats (5 women, age at examination 35–70 years old, mean 54), 
and 10 asymptomatic persons 39–47 CAG repeats (9 women, age 
at examination 23–60 years, mean 41). The symptomatic group 
was slightly older on average (p =  0.04), but their mean CAG 
repeat number did not differ (p > 0.05, paired t-test). The com-
plete demographic characteristics and assessment of the clinical 
features are provided in Table 1. Ten individuals (five women, age 
at examination 23–64 years old, mean 48) without neurological or 
psychiatric disease were included as controls. An overview about 
the neuropsychological and behavioral tests results is provided 
in Table 2.
Magnetization Transfer
In the ROI cluster analysis of the NC, fuzzy clustering was per-
formed to associate this subregion to a cluster representative for 
each group. The cluster analysis of the patients and controls was 
performed according to the MR parameter subset (T2f, SDf, kf, 
kr, T2r), given a maximal number of six classes. There was a clear 
separation into two main clusters: the first cluster encompassed 
HD mutation carriers with a disease burden (DB) exceeding 
268 (n = 11). The other important cluster contained the normal 
controls and cases with low DB. In between were cases with 
medium DBS, and this encompassed three clusters (Figure 2). We 
computed the factor loading—the relative contributions of the 
individual mMT parameter to the main components (first  and 
second principal component). The first two components explain 
94.4% of the variance. The first component that is dominated 
by the mMT parameters explains 84% of the variance. From 
Figure 3, it can be depicted that the individual contributions of 
each mMT parameter is essential for the segregation and that the 
classification is mainly driven by the characteristic macromolecu-
lar interactions and not simply by atrophy. We further calculated 
the individual gray matter/total intracranial volume ratios for 
patients (0.42 ± 03), carriers (0.48 ± 03), and HC (0.48 ± 03). 
While there was as significant difference between patients and 
carriers/HC (p < 0.001), we identified no such differences between 
carriers and healthy controls (p = 0.7, one-way ANOVA).
DiscUssiOn
In this pilot study, we investigated the potential of a region-
based mMT analysis of the NC to segregate symptomatic HD 
gene carriers from healthy controls and non-affected HD car-
riers. Automated fuzzy clustering of the patients encompass-
ing several mMT parameters (T2f, SDf, kf, kr, T2r) classified 
patients with a high DBS >268 (including one asymptomatic 
patient with high DBS) from individuals with intermediate 
DBS between 230 and 268 and from those with a low DBS 
(<230) and normal elderly controls with a sensitivity of 97%. 
Asymptomatic HD carriers were segregated from HC by mMT 
along a “transition zone” that corresponded to increasing DB 
values. The morphometric analysis of GM/TIV volume ratios 
did—in contrast to the mMT parameters—not discriminate 
between carriers and HC. These finding suggest a relationship 
between DBS and load of macromolecules in the NC. As an 
exception, one asymptomatic gene carrier with a high DBS was 
categorized within the cluster of HD patients. This “erroneous” 
clustering emphasizes a drawback of clinical scoring systems 
in defining a clear cut symptom onset beyond a consideration 
solely based on progressing motor symptoms. In HD, similar to 
other neurodegenerative disorders, cognitive and/or behavioral 
decline may appear subtle and unrecognized far prior to motor 
ones, and thus a revision of the diagnostic criteria has been 
suggested (16).
Volumetric structural image analysis by MRI is the accepted 
standard procedure to quantify atrophy in HD. Decreased cau-
date and putamen volume distinguishes subjects with HD normal 
controls and has been demonstrated to track disease progression. 
TaBle 2 | Neuropsychological tests (clinically asymptomatic gene carriers and 
symptomatic Huntington’s disease patients).
carriers (n = 10) Manifest (n = 10)
Word fluency (letters) 41.5 13.9 17.4 12.3
stroop
Naming 78.3 13.8 35.6 17.7
Reading 86.4 18.1 40.7 20.6
Interference 50.5 11.6 22.1 12.2
Symbol digit 48.8 6.8 18.2 11.0
Word fluency (category) 23.2 4.1 10.1 5.5
Trail making
A 23.6 6.5 103.6 63.5
B 70.4 22.6 207.6 50.5
Problem Behaviors assessment (short)
Depression 3.0 3.4 4.4 5.0
Irritability 
aggression
1.6 2.0 2.7 2.6
Psychosis 0.2 0.6 0.9 1.3
Apathy 0.2 0.6 4.1 3.8
Executive function 0.0 0.0 6.0 4.8
FigUre 2 | A region-of-interest cluster analysis of the nucleus caudatus was performed with fuzzy clustering to associate this subregion to a cluster representative 
for each group. The cluster analysis of the patients and controls was performed according to the MR parameter subset (T2f, SDf, kf, kr, T2r), given a maximal 
number of six classes. Each subgroup (symptomatic, presymptomatic, and control) consists of 10 persons. Cluster 4 represents subjects with a disease burden 
score (DBS) of ≥268 (yellow), it includes all symptomatic Huntington’s disease patients and one non-symptomatic gene carrier. Cluster 5 represents the non-
symptomatic gene carrier with DBS <230 and controls (black). Clusters 1, 2, and 6 (red, light and dark blue) essentially represent transition zones consisting of 
presymptomatic patients with DBS values increasing with decreasing distance from cluster 4. Cluster 3 is empty. The axes correspond to the largest eigenvalues 
found by the principal component analysis.
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Biomarker studies as TRACK-HD and PREDICT-HD revealed 
promising results in the assessment of disease progression in 
premanifest and early HD (17, 18). A volume reduction predomi-
nantly in the putamen to intracranial volume ratio, further in the 
NC, hippocampus, globus pallidus, nucleus accumbens and thala-
mus, and lobar gray matter, but not in the lobar white matter, and 
an increase in volume of cerebral fluid was associated with disease 
progression when using an automated segmentation procedure. 
However, a potential limitation of volumetric measures in drug 
studies is that potential effects may not necessarily decrease with 
brain atrophy in the presence of a meaningful clinical benefit. 
Quantitative mMT imaging in this sense, offers the opportunity 
to directly assess macromolecular tissue compositions presum-
ably reflecting microstructural damage related to HD pathology 
independently from brain atrophy. Notably, we incorporated 
solely the NC into our analysis, since it reflects the candidate area 
for earliest microstructural changes. One early phenomenon 
described in several models is the formation of inclusion bodies 
made of abnormal HTT with elongated polyglutamate track in 
nuclei and dystrophic neuritis (19). The mechanisms underlying 
the formation of these inclusion are complex, the elongation of 
the protein itself may lead to a disturbed intracellular clearance 
with accumulation, but decreased apoptotic signaling, increased 
cytosolic calcium concentration, and relative NMDA receptor 
affinity among other mechanisms, may play a role as well (20). 
The burden of these inclusions correlates with the number of 
CAG triplet repeats (21). The formation of HTT inclusion bod-
ies is accompanied by changes in the cytosolic macroprotein 
conformations. Accumulations of various proteins, including 
heat-shock protein chaperones, ubiquitin, and other components 
of the proteasome system (21) and numerous protein–protein 
interactions perturbed by elongated HTT (22) may affect the 
interactions between free and restricted protons and thus reflect 
FigUre 3 | Combined presentation of the factor loadings and the classification of the cohort under investigation. The axes indicate the main components of the 
principal component analysis. The dotted lines indicate the relative contribution of the model-based magnetization transfer (mMT) parameters T2f, SDf, kf, kr, and 
T2r extracted from the caudate nucleus (NC) in the left and right hemisphere to the segregation between HC, Huntington’s disease (HD) carriers and manifest HD 
patients. HD patients are displayed in yellow, HD carriers in blue, and healthy controls in black.
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physical properties in the presence of solid structural components 
detectable by mMT.
Several studies have addressed MT imaging, yet focusing 
on the MTR. A reduction of the MTR peak height in gray and 
white matter in manifest HD compared to healthy controls (23) 
has been reported, but no differences between presymptomatic 
gene carriers and controls. These studies concluded that there 
is no role for MTR as a biomarker in presymptomatic HD (24). 
The shortcomings of these studies are their strict focus on MTR: 
MTR is influenced by T1 effects and T2-relaxometry and does 
not differentiate between effects related to the fractional deposit 
of macromolecules and those related to the coupling of restricted 
protons. MT imaging has been consistently applied as an overall 
measure to various other neurodegenerative disorders, e.g., 
Alzheimer disease (25), Parkinson disease (26, 27), and progres-
sive supranuclear palsy (28), however, MTR lacks the specific 
properties to identify the constituents of tissue that are essential 
to identify all tissue components that dominate the MT exchange 
process in GM separately. Very recently, a similar method has 
been applied to investigate HD-related myelin breakdown in WM 
(29). Quantified MT parameters that reflect the relative density of 
the macromolecular pool were highly sensitive to microstructural 
changes related to the myelin content of WM in HD patients. 
Quantified mMT is straightforward also in GM, since it is 
targeted against disease-related macromolecule deposits instead 
of volumes in the cortex or white matter which tend to be affected 
later during the disease process.
Our pilot study provides first evidence that this method may 
be also of potential value in the classification of gene carriers as 
a potential marker of disease progression, unrelated to global 
atrophy. MT parameters that reflect an increased load of inter-
stitial water (T2f) and that are indicators of aging and atrophy, 
did not result in a clustering modifications in a previous study 
on pre-AD subjects (14), indicating that structural changes are 
minor during early preclinical stages. At the current stage the 
complete set of mMT parameters provided the most accurate 
classification with respect to the DBS, as can be seen from the 
distribution of the factor loadings displayed in Figure 3. This 
observation can be explained by the fact that the complexity of 
the interaction of macromolecules with its immediate environ-
ment cannot be adequately described by a single oversimplified 
parameter such as the MTR whereas the MT model parameters 
account for the associated complex exchange and coupling 
phenomena.
This study has limitations. The number of patients was small, 
and the investigations were focused on a PCA supervising an 
established fuzzy clustering algorithm to segregate controls, 
gene carriers, and symptomatic individuals. To investigate 
8Wiest et al. mMT Imaging in HD
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the relationship strength between the clustering with clinical 
phenotype assessment, larger longitudinal studies are necessary 
to characterize macromolecule conformations, sensitivity and 
specificity of the individual mMT parameters. Other multivari-
ate statistical methods, as, e.g., discriminant function analysis 
may be alternatively employed to test the prediction accuracy 
of mMT and subsequent disease monitoring from prodromal 
stages into HD in vivo.
Further in  vitro experiments of the concentration-related 
interactions of macromolecules are also mandatory, using 
synthetic biological multi-compartment matrices that contain 
various macromolecules (huntingtin, ubiquitin, and tau-protein) 
and different synthetic environments.
Multiparametric MRI protocols that record a compound of 
several biomarkers reflecting atrophy, protein load, and meta-
bolic processes within a single MR exam have meanwhile become 
feasible with reasonable overall acquisition times of 30–40 min 
that render mMT applicable as a complement for HD imaging 
protocols in future clinical trials.
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